Phase 2
Completed N=35
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
HCV Infection
Source: ClinicalTrials.gov NCT00726882 ↗
Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Jan 2015
Primary outcomePrimary: Persistence of Resistance-Associated Variants and Phenotypic Resistance — 4; 0; 2; 0 participants
Summary
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Persistence of Resistance-Associated Variants and Phenotypic Resistance |
4; 0; 2; 0 | — |
| SECONDARY Number of Participants With Serious Adverse Events Related to Study Procedures |
— | — |
Eligibility Criteria
Inclusion Criteria
- Main Selection Criteria: Subject received ABT-333 or matching placebo in a prior clinical study involving ABT-333.
Exclusion Criteria
- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in prior ABT-333 clinical study.
Data sourced from ClinicalTrials.gov (NCT00726882). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.